UCB to acquire Candid in $2.2B bet on bispecifics for autoimmune diseases
BioPharma Dive
The buyout involves a portfolio of antibody drugs Candid licensed from China-based biotechs and that UCB sees as part of the next wave of care for immunological conditions.
pharminent
May 4, 2026 (Last updated: May 4, 2026)
BioPharma Dive
The buyout involves a portfolio of antibody drugs Candid licensed from China-based biotechs and that UCB sees as part of the next wave of care for immunological conditions.
